Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3785328 | 0.83 | ESR1 (0.45) | ACHETSHRCYP2A6ALDH1A1CA1 | |
| SCHEMBL14101198 | 0.80 | ESR1 (0.46) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL4918290 | 0.80 | ESR1 (0.46) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL9405363 | 0.79 | TSHR (0.50) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL2229713 | 0.71 | ALDH1A1 (0.44) | ACHETSHRALDH1A1MAPT | |
| O-Xylene SCHEMBL1060158 | 0.71 | ACHE (0.71) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| SCHEMBL1989249 | 0.70 | ACHE (0.41) | ACHETSHRCYP1A2CYP2A6NQO2 | |
| SCHEMBL1107765 | 0.69 | TSHR (0.50) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2031976 | 0.67 | ACHE (0.38) | ACHETSHRCYP1A2CYP2A6ALDH1A1 | |
| Hydrochloric Acid SCHEMBL2031981 | 0.67 | ACHE (0.38) | ACHETSHRCYP1A2CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067642-B2 | Chiral phosphorous compounds | Celtice Catalysts Limited, Nova UCD (IE) | 2011-11-29 | — | — | US | disclosed |
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | CELTIC CATALYSTS LIMITED (IE) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168456-A1 | CHIRAL PHOSPHOROUS COMPOUNDS | RPP30, PLCB3, INPP5D | ACHE 4382/4885TSHR 2211/4885CYP1A2 2307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.